News

News2025-10-18T05:46:27-04:00

[News Release] VLP Therapeutics Teams with Swedish AI Biotech Nygen Analytics on Vinnova-Funded Cancer Immunotherapy Research

Swedish-US partnership to develop predictive models that could transform personalized cancer treatment selection Gaithersburg, USA and LUND, Sweden, 11 November

2025.11.11|Press Release|

[News Release] VLP Therapeutics initiates Phase 1 clinical trial of cancer treatment with Stanford Medicine: opening the door to tumor immunotherapy with VRP technology

VLP Therapeutics, Inc. (VLPT), Maryland, US-based biotech company, announced on August 27 the initiation of a Phase 1 clinical

2025.08.27|Press Release|

[Preprint] Alphavirus replicon particle expressing IL-12 reprograms tumor-associated macrophages and neutrophils and induces anti-tumor immunity

VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at the Stanford University School of Medicine posted on August 11 a

2025.08.12|Publications|

[News release] Lyophilized SARS-CoV-2 self-amplifying RNA vaccines for microneedle Array patch delivery [Journal of Controlled Release]

VLP Therapeutics, Inc. (VLPT) researchers and their colleagues at Stanford University and the University of North Carolina at Chapel Hill

2025.06.09|Press Release|

[News Release] VLP Therapeutics wins investment from GHIT Fund for dengue vaccine clinical trial

Maryland, US-based biotech company VLP Therapeutics, Inc. (VLPT) announced today that it has been awarded an investment totaling 885 million

2025.03.17|Press Release|
Go to Top